Liquidia Corp (LQDA)
12.80
-0.18
(-1.39%)
USD |
NASDAQ |
May 03, 13:48
Liquidia Cash from Financing (TTM): 43.25M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 43.25M |
September 30, 2023 | 19.66M |
June 30, 2023 | 9.946M |
March 31, 2023 | 64.83M |
December 31, 2022 | 64.96M |
September 30, 2022 | 65.93M |
June 30, 2022 | 67.57M |
March 31, 2022 | 35.64M |
December 31, 2021 | 26.32M |
September 30, 2021 | 24.19M |
June 30, 2021 | 90.79M |
March 31, 2021 | 65.22M |
December 31, 2020 | 63.42M |
Date | Value |
---|---|
September 30, 2020 | 95.21M |
June 30, 2020 | 26.39M |
March 31, 2020 | 33.72M |
December 31, 2019 | 66.39M |
September 30, 2019 | 36.16M |
June 30, 2019 | 81.09M |
March 31, 2019 | 76.01M |
December 31, 2018 | 68.82M |
September 30, 2018 | 72.25M |
June 30, 2018 | 36.86M |
March 31, 2018 | 37.54M |
December 31, 2017 | 28.81M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
9.946M
Minimum
Jun 2023
95.21M
Maximum
Sep 2020
51.62M
Average
63.42M
Median
Dec 2020
Cash from Financing (TTM) Benchmarks
United Therapeutics Corp | -1.128B |
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 0.785M |
Protalix BioTherapeutics Inc | 24.67M |
Armata Pharmaceuticals Inc | 53.99M |